US Stock MarketDetailed Quotes
EDIT Editas Medicine
- 5.325
- +0.105+2.01%
Trading Apr 26 10:19 ET
437.90MMarket Cap-2636P/E (TTM)
5.390High5.130Low175.27KVolume5.250Open5.220Pre Close927.58KTurnover0.23%Turnover RatioLossP/E (Static)82.23MShares11.91052wk High1.25P/B407.56MFloat Cap5.11052wk Low--Dividend TTM76.54MShs Float99.950Historical High--Div YieldTTM4.98%Amplitude5.110Historical Low5.292Avg Price1Lot Size
Editas Medicine Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 25.47%-132.18M | 47.39%-22.24M | 26.13%-35.46M | -2.29%-38.71M | 27.34%-35.77M | -8.27%-177.35M | -22.24%-42.27M | -17.70%-48M | 2.85%-37.85M | 0.51%-49.23M |
| Net income from continuing operations | 30.49%-153.22M | 68.93%-18.87M | 19.21%-45.02M | 24.63%-40.29M | 2.93%-49.04M | -14.51%-220.43M | -46.58%-60.74M | -42.59%-55.73M | 3.26%-53.45M | 10.95%-50.52M |
| Operating gains losses | ---- | ---- | --0 | --0 | --1.58M | ---- | ---- | ---- | ---- | ---- |
| Depreciation and amortization | -4.31%6.06M | -7.04%1.47M | -5.61%1.51M | -3.63%1.54M | -0.90%1.54M | 25.41%6.34M | 4.37%1.58M | 34.79%1.6M | 34.40%1.6M | 33.96%1.56M |
| Other non cash items | --1.6M | ---- | ---- | -340.68%-780K | -396.15%-693K | ---- | ---- | ---- | -134.77%-177K | -41.65%234K |
| Change In working capital | -119.50%-1.59M | -167.27%-8.09M | 777.31%4.56M | -158.08%-4.4M | 153.01%6.33M | 138.19%8.18M | 555.55%12.02M | 103.90%520K | 604.09%7.57M | -83.08%-11.94M |
| -Change in receivables | -3.36%-5.04M | -54.53%-7.77M | -122.93%-136K | -410.17%-2.04M | 543.71%4.9M | -184.38%-4.88M | -31,306.25%-5.03M | 641.25%593K | 93.26%659K | -120.55%-1.11M |
| -Change in prepaid assets | -43.80%-197K | -118.02%-968K | -86.83%160K | -17.06%-947K | 1,673.74%1.56M | -103.67%-137K | -119.16%-444K | 129.58%1.22M | -189.59%-809K | -102.14%-99K |
| -Change in payables and accrued expense | -82.37%2.62M | -89.05%1.5M | 1,119.35%4.74M | -176.49%-4.49M | 120.66%870K | 380.36%14.87M | 92.41%13.68M | 89.85%-465K | 2,136.46%5.87M | 44.20%-4.21M |
| -Change in other current assets | 141.67%6.63M | 75.70%-4.58M | 227.17%2.37M | 17.69%3.03M | 162.51%5.8M | -309.90%-15.92M | -830.19%-18.84M | -174.25%-1.87M | -70.21%2.58M | 135.88%2.21M |
| -Change in other current liabilities | -131.93%-5.61M | -83.55%3.73M | -346.88%-2.58M | 101.65%48K | -111.76%-6.81M | 267.41%17.57M | 786.66%22.65M | 166.69%1.04M | 65.33%-2.91M | -216.91%-3.22M |
| -Change in other working capital | ---- | ---- | ---- | ---- | ---- | 85.32%-3.33M | --0 | --0 | 1,545.70%2.18M | 0.70%-5.52M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 25.47%-132.18M | 47.39%-22.24M | 26.13%-35.46M | -2.29%-38.71M | 27.34%-35.77M | -8.27%-177.35M | -22.24%-42.27M | -17.70%-48M | 2.85%-37.85M | 0.51%-49.23M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -103.27%-3.73M | 328.28%62.84M | -215.23%-102.82M | 424.39%12.98M | -58.73%23.27M | 309.43%114.07M | -20.53%-27.53M | 324.97%89.23M | -183.53%-4M | 1,637.70%56.37M |
| Net PPE purchase and sale | -15.10%-4.72M | -109.46%-1.31M | 61.07%-239K | -117.10%-1.33M | 18.15%-1.84M | 48.60%-4.1M | 78.07%-624K | 73.81%-614K | 77.29%-614K | -2,576.19%-2.25M |
| Net investment purchase and sale | -99.16%988K | 338.43%64.15M | -214.18%-102.58M | 522.52%14.32M | -57.17%25.11M | 354.18%118.17M | -34.55%-26.9M | 340.75%89.84M | -145.20%-3.39M | 1,661.39%58.62M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -103.27%-3.73M | 328.28%62.84M | -215.23%-102.82M | 424.39%12.98M | -58.73%23.27M | 309.43%114.07M | -20.53%-27.53M | 324.97%89.23M | -183.53%-4M | 1,637.70%56.37M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 9,093.07%118.04M | -16.96%514K | 0 | 31,923.16%117.53M | 0 | -99.54%1.28M | -41.44%619K | -96.79%80K | -97.85%367K | -99.92%218K |
| Net common stock issuance | --117.08M | --0 | --0 | ---- | ---- | --0 | --0 | --0 | ---- | ---- |
| Proceeds from stock option exercised by employees | -25.23%960K | -16.96%514K | --0 | 21.53%446K | --0 | -96.07%1.28M | -41.38%619K | -96.79%80K | -97.85%367K | -98.18%218K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 9,093.07%118.04M | -16.96%514K | --0 | 31,923.16%117.53M | --0 | -99.54%1.28M | -41.44%619K | -96.79%80K | -97.85%367K | -99.92%218K |
| Net cash flow | ||||||||||
| Beginning cash position | -29.89%145.4M | -59.73%86.42M | 29.67%224.69M | -38.12%132.9M | -29.89%145.4M | 44.47%207.4M | -18.65%214.58M | -49.29%173.28M | -40.14%214.76M | 44.47%207.4M |
| Current changes in cash | 71.18%-17.87M | 159.43%41.11M | -434.79%-138.28M | 321.30%91.8M | -269.80%-12.5M | -197.12%-62M | -22.74%-69.18M | 152.99%41.3M | -142.80%-41.48M | -96.58%7.36M |
| End cash Position | -12.29%127.53M | -12.29%127.53M | -59.73%86.42M | 29.67%224.69M | -38.12%132.9M | -29.89%145.4M | -29.89%145.4M | -18.65%214.58M | -49.29%173.28M | -40.14%214.76M |
| Free cash flow | 24.56%-136.9M | 45.11%-23.55M | 26.57%-35.7M | -4.07%-40.04M | 26.94%-37.61M | -5.64%-181.47M | -14.62%-42.9M | -12.73%-48.62M | 7.64%-38.48M | -3.86%-51.48M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
